Dyax Corp. Announces Expansion of Research Agreement with Trubion Pharmaceuticals, Inc.

24-May-2007

Dyax Corp. announced that Trubion Pharmaceuticals, Inc. has exercised an option to expand its existing research agreement, which covers protein therapeutics and diagnostics discovery. In addition to the ongoing multiple-target funded research project, Dyax will now transfer its proprietary phage library to Trubion's facility for use in identifying therapeutic leads to additional targets, further enabling Trubion's ability to rapidly design and develop product candidates for a range of disease targets. Additional terms of the expanded agreement were not disclosed.

"We are excited Trubion has expanded its research agreement to further take advantage of our proprietary phage display technology," commented Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax. "This expanded agreement continues to validate our technology as a powerful tool for accelerating discovery and development of therapeutic agents and, additionally, confirms the success of our Licensing and Funded Research Program (LFRP)."

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures